Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.91 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL2188 | 1.00 | — | — | |
| Tromethamine SCHEMBL2313359 | 1.00 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL9580813 | 1.00 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL1524832 | 1.00 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL1533756 | 1.00 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL1270294 | 1.00 | MEN1 (0.91) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL8135568 | 0.96 | MEN1 (0.83) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL27944889 | 0.96 | MEN1 (0.83) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL1417748 | 0.96 | MEN1 (0.83) | MEN1LMNAKMT2AS1PR1KDM4E | |
| Tromethamine SCHEMBL7193878 | 0.96 | MEN1 (0.83) | MEN1LMNAKMT2AS1PR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113133989-B | Long-acting preparation for antituberculosis drug rifampicin and preparation method thereof | 西安医学院 | 2023-04-25 | — | — | CN | claimed |
| US-20110118457-A1 | METHOD FOR NUCLEIC ACIDS ISOLATION | LUMINEX CORPORATION | 2011-05-19 | — | — | US | claimed |
| US-5451502-A | Restriction amplification assay | ONCOR, INC. (US) | 1995-09-19 | — | — | US | claimed |
| US-11912715-B2 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11840709-B2 | Mitochondria isolation | NAGATA TAKAKO (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230365580-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-3196191-B1 | 2-ALKYLOXY BENZENE FORMYL ARYLAMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | UNIV FUDAN (CN) | 2023-04-19 | — | — | EP | disclosed |
| EP-4013500-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3426656-B1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| WO-2021005586-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2021-01-14 | — | — | WO | disclosed |
| EP-0855028-A4 | METHOD FOR QUANTITATING AN INFLAMMATORY RESPONSE | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6200757-B1 | PREFERENTIAL CHAIN ELONGATION OF A PRIMER; MIX BLOCKING AGENT AND PRIMERS, HEAT MIXTURE CAUSING THE BLOCKING AGENT TO IRREVERSIBLY DENATURE FROM PRIMER AND PERMIT CHAIN EXTENSION, RECOVER PREFERENTIAL PRODUCTS | DADE BEHRING INC. | 2001-03-13 | — | — | US | disclosed |
| US-6013478-A | PRODUCING MODIFIED HUMAN POLYPEPTIDES IN CELLS; CULTURING CELL TRANSFORMED WITH A REPLICABLE EXPRESSION VECTOR CONTAINING MODIFIED NUCLEOTIDE AND AMINO ACID SEQUENCES, RECOVERING THE EXPRESSED PRODUCT POLYPEPTIDE | GENENTECH, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| US-5834250-A | REPLACEMENT OF SEGMENT OF POLYPEPTIDE; CALIBRATION | GENENTECH, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0855028-A1 | METHOD FOR QUANTITATING AN INFLAMMATORY RESPONSE | Merck & Co., Inc. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011369-A1 | METHOD FOR QUANTITATING AN INFLAMMATORY RESPONSE | MERCK & CO., INC. (US) | 1997-03-27 | — | — | WO | disclosed |
| US-5302527-A | Nitrate reductase as marker for filamentous fungi | GLAXO GROUP LIMITED (GB) | 1994-04-12 | — | — | US | disclosed |
| US-4743553-A | Synthetic genes for bovine parainfluenza virus | W. R. GRACE & CO. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0050487-A1 | Pharmaceutical compositions comprising a benzodiazepine drug and a phenanthridine derivative | PFIZER INC. (US) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365580-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, FGFR3, COL2A1 | MEN1 3662/4885LMNA 1230/4885KMT2A 3453/4885 |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | MEN1 3349/4885LMNA 1466/4885KMT2A 1755/4885 |
| US-20110118457-A1 | METHOD FOR NUCLEIC ACIDS ISOLATION | NSUN2, POLRMT, POLN | MEN1 2194/4885LMNA 289/4885KMT2A 238/4885 |
| US-11912715-B2 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | ZC3HAV1, ZC3HAV1L, CUL5 | MEN1 2159/4885LMNA 1430/4885KMT2A 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.